Source:http://linkedlifedata.com/resource/pubmed/id/19278337
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
2009-3-23
|
pubmed:abstractText |
Antiviral antibody production during respiratory syncytial virus (RSV) infection in infants is poorly understood. To characterize local B lymphocyte responses, lung tissue and secretions from infants with RSV bronchiolitis were analyzed for innate B cell-stimulating factors and antiviral antibodies. In lung tissues of infants with fatal RSV bronchiolitis, CD20(+) lymphocytes and IgM-positive, IgG-positive, and IgA-positive plasma cells were prominent but CD4(+) T lymphocytes were not. Type I interferon-induced proteins and B cell tropic factors, including B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL), were colocalized in infected epithelium. In nasopharyngeal secretions from infants who survived RSV infection, class-switched antiviral and antinucleosomal antibodies were detected at presentation and correlated with BAFF and APRIL levels. Expression of APRIL and antiviral antibodies of IgA and IgM but not IgG isotype predicted better oxygen saturation. We conclude that B lymphocyte-stimulating factors derived from infected epithelium are primary determinants of the mucosal antibody response in infant RSV bronchiolitis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0022-1899
|
pubmed:author |
pubmed-author:AvendanoLuisL,
pubmed-author:CoyleAnthony JAJ,
pubmed-author:HintzKarenK,
pubmed-author:LumaJaysonJ,
pubmed-author:McKinneyLuannL,
pubmed-author:ReedJennifer LJL,
pubmed-author:SimsGary PGP,
pubmed-author:VelozoLuisL,
pubmed-author:WelliverRobert CRCSr,
pubmed-author:WelliverTimothy PTP
|
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
199
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1128-38
|
pubmed:meshHeading |
pubmed-meshheading:19278337-Antibodies, Viral,
pubmed-meshheading:19278337-B-Lymphocytes,
pubmed-meshheading:19278337-Humans,
pubmed-meshheading:19278337-Immunity, Innate,
pubmed-meshheading:19278337-Immunoglobulins,
pubmed-meshheading:19278337-Infant,
pubmed-meshheading:19278337-Lung,
pubmed-meshheading:19278337-Oxygen,
pubmed-meshheading:19278337-Respiratory Syncytial Virus Infections,
pubmed-meshheading:19278337-Signal Transduction,
pubmed-meshheading:19278337-T-Lymphocytes
|
pubmed:year |
2009
|
pubmed:articleTitle |
Innate immune signals modulate antiviral and polyreactive antibody responses during severe respiratory syncytial virus infection.
|
pubmed:affiliation |
Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA. jennifer.reed@fda.hhs.gov
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|